Cargando…
Effect of Montelukast on Bronchopulmonary Dysplasia (BPD) and Related Mechanisms
BACKGROUND: Bronchopulmonary dysplasia (BPD) is a chronic lung disease common in preterm infants. Montelukast, an effective cysteinyl leukotriene (cysLT) receptor antagonist, has a variety of pharmacological effects and has protective effects against a variety of diseases. Currently, the efficacy an...
Autores principales: | Chen, Xin, Zhang, Xiaoqian, Pan, Jiahua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6427930/ https://www.ncbi.nlm.nih.gov/pubmed/30862773 http://dx.doi.org/10.12659/MSM.912774 |
Ejemplares similares
-
Stem-Cell Therapy for Bronchopulmonary Dysplasia (BPD) in Newborns
por: Omar, Said A., et al.
Publicado: (2022) -
Systemic Steroids in Preventing Bronchopulmonary Dysplasia (BPD): Neurodevelopmental Outcome According to the Risk of BPD in the EPICE Cohort
por: Zayat, Noura, et al.
Publicado: (2022) -
The efficacy and safety of Montelukast sodium in the prevention of bronchopulmonary dysplasia
por: Kim, Sang Bum, et al.
Publicado: (2015) -
Chitin-Derived AVR-48 Prevents Experimental Bronchopulmonary Dysplasia (BPD) and BPD-Associated Pulmonary Hypertension in Newborn Mice
por: Das, Pragnya, et al.
Publicado: (2021) -
Respiratory Morbidity and Lung Function Analysis During the First 36 Months of Life in Infants With Bronchopulmonary Dysplasia (BPD)
por: Chen, Dandan, et al.
Publicado: (2020)